SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

A sharp AVAX rebound and technical breakout, including a move back above the 200-day moving average, has drawn attention amid broader altcoin strength. Traders are divided between bullish calls for continued momentum and skepticism that the move will hold, citing weak volume, repeated selloffs, and token-inflation concerns.

Digital Turbine, Inc. engages in mobile growth platform solutions for advertisers, publishers, carriers, and device original equipment manufacturers. It operates through the following segments: On Device Solutions and App Growth Platform. The On Device Solutions segment consists of products and services that simplify the discovery and delivery of mobile apps and content media for device end users. The App Growth Platform segment provides Advertising Solutions and Ad Monetization Solutions. The company was founded on November 6, 1998 and is headquartered in Austin, TX.

Digital Turbine Inc

A strong quarterly earnings beat and upbeat guidance have driven attention, with traders highlighting improving growth, cash flow, and a potential ad-tech re-rating. The bullish reaction is tempered by debate over profit-taking, options-related volatility, short pressure, and whether the post-earnings rally can hold.

Arbutus Biopharma Corp. is a clinical-stage biopharmaceutical company, which engages in developing novel therapeutics that target specific viral diseases. It focuses on the development of imdusiran (AB-729), proprietary, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic, and AB-101, proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). The company was founded on October 6, 2005 and is headquartered in Warminster, PA.

Arbutus Biopharma Corp

Arbutuss modified Dutch-auction tender offer is driving attention, with traders debating whether to tender shares or hold for potential value from a reduced share count and future litigation or HepB catalysts. Some view the offer as a valuation floor and short-covering setup, while others worry it could suppress the stock and strengthen Roivants position at shareholders expense.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Kylian Mbapps departure from Nike for On is fueling concern that the brand is losing high-profile athletes and market share in soccer, though some traders view the exit as a cost-saving move involving an overrated endorser. The debate is occurring alongside broader worries about Nikes weak growth, management, competition and persistent share-price declines.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

A reported Bonk DAO exploit and related exchange-delisting concerns are driving attention, with traders linking the security incident to BONKs sharp selloff and questioning whether the team will resolve the flaw. Some participants are buying the dip and expecting a recovery if a fix arrives or broader Solana and meme-coin momentum returns, while others view the token as highly risky or potentially headed lower.

XYO is the original and one of the largest Decentralized Physical Infrastructure Networks (DePIN), boasting over 10 million nodes and consistently leading DePIN in both scale and revenue generation. Launching its Mainnet ahead of any other DePIN, XYO specializes in collecting and validating real-world data, bridging it seamlessly to Web3 and Web2 companies across AI, geolocation, and other critical data sectors. At the core of XYO are Proof of Location and Proof of Origin technologies, enabling accurate validation of real-world data for innovative use cases such as Real-World Asset (RWA) tracking, DePIN applications, real-world gaming, and treasure hunts. Recently, XYO expanded its ecosystem by launching the XYO Layer One blockchain, purpose-built to support the intensive data demands of DePIN, RWA, AI, and similar data-driven industries. XYO employs a unique dual-token model: XYO Token: An externally traded token supporting the DePIN ecosystem, rewards, staking, and governance, enhancing overall ecosystem value and scarcity.   XL1 Token: Internal to the XYO Layer One blockchain, facilitating transactions, gas fees, and other blockchain-specific use cases. The dual-token economics are strategically designed to increase scarcity and promote sustainable growth. The XYO token is available on major exchanges, including Coinbase. The XL1 token will launch publicly later in 2025. To accelerate network adoption and growth, XYO created the popular COIN app. Beyond the XYO Foundation, the team founded the U.S.-based, for-profit entity XY Labs Inc., notable as the first U.S. crypto company qualified by the SEC for a Regulation A offering, permitting share sales to both accredited and non-accredited investors. XY Labs further stands out as one of the pioneering U.S. companies to tokenize and publicly list its shares. These tokenized shares trade as $XYLB on the tZERO ATS, positioning XY Labs prominently in the growing wave of Real-World Asset (RWA) tokenization.

XYO Network

Attention centers on XYOs repeated short-lived pumps and retracements, with traders citing weak volume, possible bot activity, and concerns that the related XL1 token is diverting attention from XYO. Some holders remain bullish on its AI/DePIN use cases and speculate about future partnerships, but those catalysts are unconfirmed and widely debated.

Cronos is an institutional-grade, high-performance, EVM-compatible Layer-1 blockchain built on the Cosmos SDK and integrated with the Inter-Blockchain Communication (IBC) protocol, designed as the backbone for open, compliant, and AI-accessible tokenized markets. It supports up to 60,000 transactions per second (TPS), 500ms block times, instant finality, and sub-$0.01 fees via Proof of Authority consensus.

Crypto.com Coin

Speculation around a potential CRO ETF and related regulatory developments is driving attention, with traders debating repeated approval delays rather than citing a confirmed launch. The community remains divided, as bullish expectations for an ETF, a new Cronos app and institutional interest compete with concerns about token emissions, past unburned supply and persistent selling pressure.

Grayscale Investments LLC - Grayscale Zcash ETF

Grayscale Zcash Trust ZEC

Grayscales planned 3-for-1 forward split is the primary catalyst, with traders viewing the lower post-split share price and improved accessibility as supportive for liquidity and demand amid Zcashs rally. The community is broadly bullish, though some traders debate ZCSHs lag versus ZEC and its premium or discount to net asset value.

Hunter Biden’s Laptop (LAPTOP) is a memecoin referencing the eponymous Hunter Biden laptop sensation that’s been a fixture in global media news cycles for the past six years. LAPTOP is a fungible, freely transferable, non-yield-bearing ERC-20 token on Base. As a memecoin, LAPTOP has no utility, but incorporates two novel distribution mechanics designed to promote long-term community growth: a large community airdrop and an event-based supply mechanism.

Hunter Biden's Laptop

Hunter Bidens $LAPTOP.X meme coin launch and abrupt, near-total selloff have driven attention, with traders widely describing the move as a rug pull or scam. A smaller group is buying or holding in hopes of a speculative rebound, while others question the tokens utility and legality.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Attention is centered on Auvelitys early launch for Alzheimers-related agitation, with traders highlighting rising new prescriptions, strong uptake among older patients, and bullish commentary from recent healthcare conferences and analysts. The community remains divided over whether weekly prescription data is accelerating or undercounted because of samples and long-term-care reporting lags, contributing to debate around the stocks low-volume pullback.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference Intensity Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference PR Newswire SHELTON, Conn., Sept. 8, 2026 SHELTON, Conn., Sept. 8, 2026 /PRNewswire...

NTHI Heads into Wednesday with a Rare Biotech Convergence: Brain-Cancer Data, Tight Float, and Analyst Targets

DENVER, Colo. ( 247marketnews.com ) — NeOnc Technologies (NASDAQ:NTHI) is heading into Wednesday with the kind of setup that can put a clinical-stage biotech squarely on the market’s radar: a stock tr...

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update Intensity Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update PR Newswire SHELTON, Conn., Aug. 11, 2026 Initiated activities to resume enrollment in a limited number...

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026

Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 Intensity Therapeutics to Announce Second Quarter 2026 Financial Results on August 11, 2026 PR Newswire SHELTON, Conn., Aug. 4, 2026 Company to hold a conference call at 8AM ET on August 11, 2026 to review...

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study)

Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical...

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6

Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 Intensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6 PR...

Intensity Therapeutics Inc. (INTS) Upgraded to Buy: Here's Why

Intensity Therapeutics Inc. (INTS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award

Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award Intensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award PR Newswire...

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Intensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update PR...

Intensity Therapeutics Inc. (INTS) Could Find a Support Soon, Here's Why You Should Buy the Stock Now

Intensity Therapeutics Inc. (INTS) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

This account has been verified as an official INTS representative.

Verified Account

Intensity Therapeutics

Reported GAAP EPS of -$1.11 up 66.96% YoY

Intensity Therapeutics reported an increased net loss and higher research and development expenses, while the company faces significant risks regarding future funding requirements and potential delisting from the Nasdaq exchange.

Intensity Therapeutics resumed enrollment for its Phase 3 INVINCIBLE-3 study, while preliminary INVINCIBLE-4 data demonstrated a higher pathological complete response rate and reduced grade 3 adverse events for the company.

Intensity Therapeutics, Inc. is a clinical-stage biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.

Intensity Therapeutics Inc

Why Did INTS Stock Plummet 25% Today? 

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Current Price	$4.11
Prev Close	$3.88
Open	$3.79
Dividend Yield	0.00%
50-Day Moving Average	$4.32
Beta	0.27
Avg. Volume	37,790.02
PE Ratio	-0.85

52-Week High	$43.50
52-Week Low	$3.51
Market Capitalization	$12.67M
EPS (Annual)	-$8.56
Price to Book	1.31
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

INTS Fundamentals